SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-19-043378
Filing Date
2019-11-14
Accepted
2019-11-14 08:50:19
Documents
66
Period of Report
2019-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q fulc-10q_20190930.htm 10-Q 2611535
2 EX-31.1 fulc-ex311_8.htm EX-31.1 11524
3 EX-31.2 fulc-ex312_7.htm EX-31.2 12332
4 EX-32.1 fulc-ex321_9.htm EX-32.1 6292
5 EX-32.2 fulc-ex322_6.htm EX-32.2 6194
  Complete submission text file 0001564590-19-043378.txt   6886810

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT fulc-20190930.xml EX-101.INS 1186005
7 XBRL TAXONOMY EXTENSION SCHEMA fulc-20190930.xsd EX-101.SCH 47708
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE fulc-20190930_cal.xml EX-101.CAL 40435
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE fulc-20190930_def.xml EX-101.DEF 215029
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE fulc-20190930_lab.xml EX-101.LAB 357971
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fulc-20190930_pre.xml EX-101.PRE 313994
Mailing Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139
Business Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 617-651-8851
Fulcrum Therapeutics, Inc. (Filer) CIK: 0001680581 (see all company filings)

IRS No.: 474839948 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38978 | Film No.: 191216656
SIC: 2834 Pharmaceutical Preparations